Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 5, Issue 4, Pages 431-437Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2005.03.003
Keywords
-
Categories
Funding
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
Siglecs are sialic acid-binding Ig-like lectins expressed in a highly specific manner, and which are implicated in signaling and adhesive functions. The CD33-related siglecs represent a distinct subgroup that is undergoing rapid evolution within the innate immune system, with the potential to trigger apoptosis and provide inhibitory signals. CD22 is a well-characterised B cell restricted siglec that has been shown to mediate both sialic acid-dependent and independent signaling functions in B cell regulation. As endocytic receptors, siglecs provide portals of entry for certain viral and bacterial pathogens, as well as therapeutic opportunities for targeting innate immune cells in disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available